Ticker Scorecard - AKBA Basics Company: Akebia Therapeutics, Inc. IPO Date: March 24, 2018 Sector: Healthcare Industry: Biotech Market Cap: $405.82M Activated in VL: True Average Daily Range Avg Daily Range: $0.14 | 3.57% Avg Daily Range (30 D): $0.05 | 2.35% Avg Daily Range (90 D): $0.04 | 2.57% Institutional Daily Volume Avg Daily Volume: 2.59M Avg Daily Volume (30 D): 2.13M Avg Daily Volume (90 D): 1.86M Trade Size Avg Trade Size (Sh.): 313 Avg Trade Size (Sh.) (30 D): 317 Avg Trade Size (Sh.) (90 D): 311 Institutional Trades Total Inst.Trades: 808 Avg Inst. Trade: $1.67M Avg Inst. Trade (30 D): $3.48M Avg Inst. Trade (90 D): $2.14M Avg Inst. Trade Volume: .47M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.59M Avg Closing Trade (30 D): $7.31M Avg Closing Trade (90 D): $2.51M Avg Closing Volume: 468.75K     News Jul 10, 2024 @ 11:04 AM Unicycive Therapeutics Announces Initial Positive ... Source: Unicycive Therapeutics, Inc. May 9, 2024 @ 12:10 PM Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses... Source: Zacks Equity Research Mar 28, 2024 @ 12:21 PM Why RH Shares Are Trading Higher By Around 9%; Her... Source: Avi Kapoor Mar 28, 2024 @ 11:06 AM Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia... Source: Zacks Equity Research Mar 27, 2024 @ 2:03 PM Cintas Reports Upbeat Earnings, Joins PaySign, Noa... Source: Avi Kapoor Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.23 $-.1 $-.04 Diluted EPS $-.23 $-.1 $-.04 Revenue $ 169.88M $ 37.43M $ 43.65M Gross Profit $ 108.4M $ 23.27M $ 26.6M Net Income / Loss $ -45.99M $ -20.04M $ -8.58M Operating Income / Loss $ -34.79M $ -12.51M $ -8.73M Cost of Revenue $ 61.48M $ 14.16M $ 17.05M Net Cash Flow $ -8.89M $ -5.47M $ -3.41M PE Ratio